The Evaluation of Meropenem Dosing Regimens Against ESBL-Producing Escherichia coli in ICU Patients Using Monte Carlo Simulation

References

• Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657–686. doi:10.1128/CMR.18.4.657-686.2005
   PubMed Web of Science ®Google Scholar
• Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007;60(5):913–920. doi:10.1093/jac/dkm318
   PubMed Web of Science ®Google Scholar
• Rottier WC, Ammerlaan HS, Bonten MJ. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother. 2012;67(6):1311–1320. doi:10.1093/jac/dks065
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. doi:10.1016/S1473-3099(17)30753-3
   PubMed Web of Science ®Google Scholar
• Chereau F, Opatowski L, Tourdjman M, Vong S. Risk assessment for antibiotic resistance in South East Asia. BMJ. 2017;358:j3393. doi:10.1136/bmj.j3393
   PubMed Web of Science ®Google Scholar
• Myat TO, Hannaway RF, Zin KN, et al. ESBL- and carbapenemase-producing Enterobacteriaceae in patients with bacteremia, Yangon, Myanmar, 2014. Emerg Infect Dis. 2017;23(5):857–859. doi:10.3201/eid2305.161100
   Web of Science ®Google Scholar
• Aung MS, San N, Maw WW, et al. Prevalence of extended-spectrum beta-lactamase and carbapenemase genes in clinical isolates of Escherichia coli in Myanmar: dominance of bla(NDM-5) and emergence of bla(OXA-181). Microb Drug Resist. 2018;24(9):1333–1344. doi:10.1089/mdr.2017.0387
   Web of Science ®Google Scholar
• Crandon JL, Ariano RE, Zelenitsky SA, Nicasio AM, Kuti JL, Nicolau DP. Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med. 2011;37(4):632–638. doi:10.1007/s00134-010-2105-0
   PubMed Web of Science ®Google Scholar
• Vinks A, Derendorf H, Mouton J, eds. Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics. New York: Springer; 2014.
   Google Scholar
• Roberts JA, Kirkpatrick CM, Lipman J. Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Chemother. 2011;66(2):227–231. doi:10.1093/jac/dkq449
   PubMed Web of Science ®Google Scholar
• Asín-Prieto E, Rodríguez-Gascón A, Isla A. Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents. J Infect Chemother. 2015;21(5):319–329. doi:10.1016/j.jiac.2015.02.001
   PubMed Web of Science ®Google Scholar
• CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI Supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.
   Google Scholar
• Thuy NTT, Thanh DD, Ha NH, Huong NTL. Population pharmacokinetics of meropenem in Vietnamese adult patients. Pharm Sci Asia. 2018;45(4):221–230. doi:10.29090/psa.2018.04.017.0042
   Google Scholar
• Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother. 2007;51(5):1725–1730. doi:10.1128/AAC.00294-06
   PubMed Web of Science ®Google Scholar
• Pifizer (homepage on Internet). Merrem IV: US physician prescribing information; 2019. Avaliable from: https://www.pfizer.com/products/product-detail/merrem_i_v. Accessed January 18, 2022.
   Google Scholar
• European Medicines Agency (homepage on Internet). Meronem: article 30 referral – annex I, II, III; 2009. Avaliable from: https://www.ema.europa.eu/en/medicines/human/referrals/meronem#overview-section. Accessed January 18, 2022.
   Google Scholar
• Ehmann L, Zoller M, Minichmayr IK, et al. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis. Int J Antimicrob Agents. 2019;54(3):309–317. doi:10.1016/j.ijantimicag.2019.06.016
   PubMed Web of Science ®Google Scholar
• Mendes RE, Mendoza M, Banga Singh KK, et al. Regional resistance surveillance program results for 12 Asia-Pacific nations (2011). Antimicrob Agents Chemother. 2013;57(11):5721–5726. doi:10.1128/AAC.01121-13
   Web of Science ®Google Scholar
• Suwantarat N, Carroll KC. Epidemiology and molecular characterization of multidrug-resistant gram-negative bacteria in Southeast Asia. Antimicrob Resist Infect Control. 2016;5:15. doi:10.1186/s13756-016-0115-6
   PubMed Web of Science ®Google Scholar
• Isla A, Canut A, Arribas J, Asín-Prieto E, Rodríguez-Gascón A. Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases. Eur J Clin Microbiol Infect Dis. 2016;35(3):511–519. doi:10.1007/s10096-015-2568-6
   Web of Science ®Google Scholar
• Mathew SK, Mathew BS, Neely MN, et al. A nonparametric pharmacokinetic approach to determine the optimal dosing regimen for 30-minute and 3-hour meropenem infusions in critically ill patients. Ther Drug Monit. 2016;38(5):593–599. doi:10.1097/FTD.0000000000000323
   PubMed Web of Science ®Google Scholar
• Guilhaumou R, Benaboud S, Bennis Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French society of pharmacology and therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French society of anaesthesia and intensive care medicine (Société Française d’Anesthésie et Réanimation-SFAR). Crit Care. 2019;23(1):104. doi:10.1186/s13054-019-2378-9
   PubMed Web of Science ®Google Scholar
• Gamper G, Havel C, Arrich J, et al. Vasopressors for hypotensive shock. Cochrane Database Syst Rev. 2016;2(2):Cd003709. doi:10.1002/14651858.CD003709.pub4
   PubMed Web of Science ®Google Scholar
• Bellomo R, Wan L, May C. Vasoactive drugs and acute kidney injury. Crit Care Med. 2008;36(4 Suppl):S179–S186. doi:10.1097/CCM.0b013e318169167f
   PubMed Web of Science ®Google Scholar
• Ma S, Evans RG, Iguchi N, et al. Sepsis-induced acute kidney injury: a disease of the microcirculation. Microcirculation. 2019;26(2):e12483. doi:10.1111/micc.12483
   PubMed Web of Science ®Google Scholar
• Lankadeva YR, Kosaka J, Evans RG, Bailey SR, Bellomo R, May CN. Intrarenal and urinary oxygenation during norepinephrine resuscitation in ovine septic acute kidney injury. Kidney Int. 2016;90(1):100–108. doi:10.1016/j.kint.2016.02.017
   PubMed Web of Science ®Google Scholar
• Asfar P, Teboul JL, Radermacher P, et al. High versus low blood-pressure target in septic shock. N Engl J Med. 2014;370(17):1583–1593. doi:10.1056/NEJMoa1312173
   PubMed Web of Science ®Google Scholar
• Grijalba AII, Aldaz Pastor A, Marquet P, Woillard JB. Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation. Eur J Clin Pharmacol. 2019;75(10):1405–1414. doi:10.1007/s00228-019-02716-y
   Web of Science ®Google Scholar